All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Liver Cancer Death Rates Defy Declining Trends

April 19, 2016
Publication
Article
HCC MonitorApril 2016
Volume 2
Issue 1

Death rates from cancer continue to drop in the United States, with one troubling exception: more people are dying from liver cancer.

The annual Report to the Nation on the Status of Cancer, issued each year since 1975, had mostly good news: an ongoing decline in cancer incidence has come from decades of progress in preventing the disease, especially in getting Americans to quit smoking. While lung cancer remains the leading cause of cancer death in both men and women, rates are dropping. New therapies are improving treatment in lung cancer and other forms of the disease, and vaccines may prevent other cancers entirely.

Liver cancer incidence rose an average of 2.3% each year, and the death rate from liver cancer rose by an average of 2.8% each year among men, and 3.4% each year among women, between 2008 and 2012. This occurred while overall cancer death rates fell 1.5% per year from 2003 to 2012.

“We have the knowledge and tools available to slow the epidemic of liver cancer in the United States, including testing and treatment for HCV, hepatitis B vaccination, and lowering obesity rates,” said Otis W. Brawley, MD, chief medical officer for the American Cancer Society. “We hope this report will help focus needed attention and resources on liver cancer.”

The report has some overlap with the findings released in November 2015 by Princeton economists Angus Deaton, FBA, and Anne Case, PhD, who analyzed years of mortality and morbidity data to find a sharp increase in the death rates of lower-income whites with poor education. This cohort had frequent problems with substance abuse, alcohol, chronic liver disease, cirrhosis, and higher rates of suicide.

“Besides strains of hepatitis, lifestyle factors are playing a role in the rise of liver cancer deaths,” said Brawley. “Many may realize that alcohol can lead to cirrhosis, or scarring, of the liver, but fewer know that obesity and diabetes can do the same thing.”

Across all racial and ethnic groups, women were twice as likely to be diagnosed with the disease, with Native Americans, Alaskans, and Asians/Pacific Islanders most at risk (this last group is vulnerable to hepatitis B virus infection, which fortunately is decreasing due to vaccination).

The connection between hepatitis C (HCV) and liver cancer was clear, with death rates from liver cancer highest among those born between 1945 and 1965—this group has 6 times the risk of HCV infection of other adults. Just over 20% of the common liver cancers are linked to HCV infection in the United States.

Both CDC and the US Preventive Services Task Force recommends that every person in this age group be screen at least once for the disease, so that treatment can begin before complications emerge. That recommendation is controversial with health plans, since treatment is costly. The first cure for HVC infection, sofosbuvir (Sovaldi), hit the market at $1000 a day for a 12-week course; while competitors have emerged, none are inexpensive.

Articles in this issue

Dr. Michael Manns on a Possible Link Between Hepatitis C and Hepatocellular Carcinoma
Dr. Michael Manns on a Possible Link Between Hepatitis C and Hepatocellular Carcinoma
Dr. Anne Covey on Locoregional Therapy in Hepatocellular Carcinoma
Dr. Anne Covey on Locoregional Therapy in Hepatocellular Carcinoma
NCCN Guideline Calls Locoregional Therapy "Curative" for HCC
NCCN Guideline Calls Locoregional Therapy "Curative" for HCC
Genetically Modified T-Cell Therapy Cleared for Early Stage HCC Study
Genetically Modified T-Cell Therapy Cleared for Early Stage HCC Study
Neoadjuvant Sorafenib Induces Major Tumor Necrosis in HCC
Neoadjuvant Sorafenib Induces Major Tumor Necrosis in HCC
Committee Recommends Continuation of Phase III Tivantinib Study
Committee Recommends Continuation of Phase III Tivantinib Study
Liver Cancer Death Rates Defy Declining Trends
Liver Cancer Death Rates Defy Declining Trends
Moving Forward: Examining the Evolving Role of Embolization in HCC
Moving Forward: Examining the Evolving Role of Embolization in HCC
New Approaches to the Detection and Treatment of HCC With Portal Vein Thrombosis
New Approaches to the Detection and Treatment of HCC With Portal Vein Thrombosis
Novel Therapies on the Horizon in Hepatocellular Carcinoma
Novel Therapies on the Horizon in Hepatocellular Carcinoma
Related Videos
Related Content
Advertisement

Cancer Centers Without Mental Health Options Should Use Online Resources

Cancer Centers Without Mental Health Options Should Use Online Resources

December 4th 2023
Article

In an interview with Peers & Perspectives in Oncology, Teresa L. Deshields, PhD, ABPP, discussed how oncologists can guide patients with cancer to mental health resources.

Read More


Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen


Cost-of-Care Conversations in Cancer Treatment Fall Short, New Study Reveals

Cost-of-Care Conversations in Cancer Treatment Fall Short, New Study Reveals

December 4th 2023
Article

New treatments can come with high price tags, and a population-based, retrospective study revealed that fewer than 25% of patients with cancer have a documented conversation about the financial aspects of their treatment.

Read More


Better QOL Observed as Testosterone  Levels Improve

Better QOL Observed as Testosterone Levels Improve

December 3rd 2023
Article

Read More


Updated Trials at ESMO Reveal New Frontline Combo in Urothelial Carcinoma

Updated Trials at ESMO Reveal New Frontline Combo in Urothelial Carcinoma

December 2nd 2023
Article

Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.

Read More


Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress 2023

Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress 2023

December 1st 2023
Article

The growing number of clinical trials testing neoadjuvant immunotherapy with or without chemotherapy has opened up new possibilities for treating locally advanced solid tumors.

Read More

Related Content
Advertisement

Cancer Centers Without Mental Health Options Should Use Online Resources

Cancer Centers Without Mental Health Options Should Use Online Resources

December 4th 2023
Article

In an interview with Peers & Perspectives in Oncology, Teresa L. Deshields, PhD, ABPP, discussed how oncologists can guide patients with cancer to mental health resources.

Read More


Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen


Cost-of-Care Conversations in Cancer Treatment Fall Short, New Study Reveals

Cost-of-Care Conversations in Cancer Treatment Fall Short, New Study Reveals

December 4th 2023
Article

New treatments can come with high price tags, and a population-based, retrospective study revealed that fewer than 25% of patients with cancer have a documented conversation about the financial aspects of their treatment.

Read More


Better QOL Observed as Testosterone  Levels Improve

Better QOL Observed as Testosterone Levels Improve

December 3rd 2023
Article

Read More


Updated Trials at ESMO Reveal New Frontline Combo in Urothelial Carcinoma

Updated Trials at ESMO Reveal New Frontline Combo in Urothelial Carcinoma

December 2nd 2023
Article

Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.

Read More


Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress 2023

Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress 2023

December 1st 2023
Article

The growing number of clinical trials testing neoadjuvant immunotherapy with or without chemotherapy has opened up new possibilities for treating locally advanced solid tumors.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.